News - Etanercept Shows Promise in Still's Disease

[Guest guest]

Etanercept Shows Promise in Still's Disease

A DGReview of : " Etanercept in the treatment of adult patients with Still's

disease "

Arthritis & Rheumatism

05/20/2002

By Anne MacLennan

Etanercept therapy appears to improve arthritis and is well tolerated in

adults with Still's disease, according to a small study.

M. Elaine Husni and colleagues from Brigham and Women's Hospital, Harvard

Medical School, Boston, Massachusetts and others from Boston and Seattle,

Washington, United States, evaluated this treatment in 12 adult patients

with Still's disease and active arthritis.

The effects of tumour necrosis factor inhibitors in Still's disease remain

to be elucidated, the authors underline.

For their six-month, open-label trial, 12 patients who met criteria for

Still's disease were treated with etanercept in biweekly doses of 25 mg. All

patients had been treated unsuccessfully with other disease-modifying

antirheumatic drugs. At study entry, mean disease duration was 10.7 years.

Treatment efficacy was evaluated by American College of Rheumatology (ACR)

improvement criteria and recorded adverse events.

Ten patients successfully completed the study, two having withdrawn because

of disease flare. In four patients, etanercept dosage was increased to 25 mg

three times per week.

Of seven patients who met ACR 20 percent response criteria, four met ACR 50

percent response criteria and two met ACR 70 percent. In the three patients

with systemic features of Still's disease (fever and rash), one patient had

some improvement in these features. However, none of the three had any

improvement in arthritis symptoms.

Other than disease flare -- rash, fever and arthritis -- in the two patients

who withdrew from the study, there were no significant adverse events.

Arthritis & Rheumatism Volume 46, Issue 5, 2002. Pages: 1171-1176.

[Guest guest]

YESM....but try to get it.....

--- a <paula54@...> wrote:

> Etanercept Shows Promise in Still's Disease

> A DGReview of : " Etanercept in the treatment of adult

> patients with Still's

> disease "

> Arthritis & Rheumatism

> 05/20/2002

> By Anne MacLennan

>

>

> Etanercept therapy appears to improve arthritis and

> is well tolerated in

> adults with Still's disease, according to a small

> study.

>

> M. Elaine Husni and colleagues from Brigham and

> Women's Hospital, Harvard

> Medical School, Boston, Massachusetts and others

> from Boston and Seattle,

> Washington, United States, evaluated this treatment

> in 12 adult patients

> with Still's disease and active arthritis.

>

> The effects of tumour necrosis factor inhibitors in

> Still's disease remain

> to be elucidated, the authors underline.

>

> For their six-month, open-label trial, 12 patients

> who met criteria for

> Still's disease were treated with etanercept in

> biweekly doses of 25 mg. All

> patients had been treated unsuccessfully with other

> disease-modifying

> antirheumatic drugs. At study entry, mean disease

> duration was 10.7 years.

>

> Treatment efficacy was evaluated by American College

> of Rheumatology (ACR)

> improvement criteria and recorded adverse events.

>

> Ten patients successfully completed the study, two

> having withdrawn because

> of disease flare. In four patients, etanercept

> dosage was increased to 25 mg

> three times per week.

>

> Of seven patients who met ACR 20 percent response

> criteria, four met ACR 50

> percent response criteria and two met ACR 70

> percent. In the three patients

> with systemic features of Still's disease (fever and

> rash), one patient had

> some improvement in these features. However, none of

> the three had any

> improvement in arthritis symptoms.

>

> Other than disease flare -- rash, fever and

> arthritis -- in the two patients

> who withdrew from the study, there were no

> significant adverse events.

> Arthritis & Rheumatism Volume 46, Issue 5, 2002.

> Pages: 1171-1176.

>

>

__________________________________________________